New technologies in cervical cancer screening.
A shift to a molecular approach to cervical cancer screening is the most likely solution to the goals of improved screening in both the developed and developing world. The impetus for new screening technologies in the developed world is predominately driven by the need to increase positive predictive value and reduce over-management of low-grade and often transient abnormalities (i.e., increase specificity). Rapid tests, where results can be given to a patient within the same visit, are anticipated to have the greatest impact in low resource settings in low and middle income countries (and in disadvantaged sub-populations in high-income countries) where substantial loss to follow up cripples the effectiveness of cervical cancer screening programs. Clinical validation will be required before these tests are implemented in routine screening programs.
Departments of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. pgravitt@jhsph.edu
Patti E
PE
Gravitt
François
F
Coutlée
Thomas
T
Iftner
John W
JW
Sellors
Wim G V
WG
Quint
Cosette M
CM
Wheeler
D005260:Female; D006801:Humans; D007182:Income / Q000145:classification; D008403:Mass Screening / Q000379:methods* / Q000458:organization & administration / Q000592:standards; D011230:Precancerous Conditions / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control*